Comparison of two lung cancer screening scores among patients with chronic obstructive pulmonary disease: A community study
- PMID: 30597746
- DOI: 10.1111/crj.12988
Comparison of two lung cancer screening scores among patients with chronic obstructive pulmonary disease: A community study
Abstract
Introduction: Based on the National Lung Cancer Screening Trial (NLST), guidelines on screening programs for lung cancer have recommended low-dose computed tomography (LDCT). De Torres et al made a score for COPD patients (COPD-LUCSS) to improve their selection criteria.
Objective: To examine and compare the discriminating value of both scores in a community-based cohort of COPD patients.
Methods: Four hundred and twenty-two ever-smokers with COPD from the GenKOLS study in Bergen were merged with the Cancer Registry of Norway. We divided the patients into groups of high and low risk according to the COPD-LUCSS and the NLST criteria. Cox regression and logistic regression were used to analyse the associations between the scores and lung cancer. We used Harrell's C and area under the curve (AUC) to estimate discriminating values and to compare the models.
Results: Hazard ratio for the high risk vs the low risk in the COPD-LUCSS was 3.0 (1.4-6.5 95% CI), P < 0.01. Hazard ratio for the NLST criteria was 2.2 (95% CI 1.1-4.5), P < 0.05. Harrell's C was 0.63 for the COPD-LUCSS and 0.59 for the NLST selection criteria. AUC was 0.61 for COPD-LUCSS and 0.59 for NLST criteria. Comparing tests showed no differences (P = 0.76).
Conclusion: Although the COPD-LUCSS and the NLST criteria were associated with increased risk of lung cancer, the AUC and Harrell's C values showed that these models have poor discriminating abilities in our cohort of COPD patients. The COPD-LUCSS was not significantly better than the NLST criteria.
Keywords: COPD; epidemiology; lung cancer; screening.
© 2018 John Wiley & Sons Ltd.
Similar articles
-
Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO.Chest. 2016 Apr;149(4):936-42. doi: 10.1378/chest.15-1868. Epub 2016 Jan 12. Chest. 2016. PMID: 26513409
-
Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.Am J Respir Crit Care Med. 2015 Feb 1;191(3):285-91. doi: 10.1164/rccm.201407-1210OC. Am J Respir Crit Care Med. 2015. PMID: 25522175 Free PMC article.
-
Lung cancer screening in clinical practice: identification of high-risk chronic obstructive pulmonary disease patients.Rev Assoc Med Bras (1992). 2022 Apr;68(4):502-506. doi: 10.1590/1806-9282.20211106. Rev Assoc Med Bras (1992). 2022. PMID: 35649074
-
The potential impact of chronic obstructive pulmonary disease in lung cancer screening: implications for the screening clinic.Expert Rev Respir Med. 2019 Aug;13(8):699-707. doi: 10.1080/17476348.2019.1638766. Epub 2019 Jul 5. Expert Rev Respir Med. 2019. PMID: 31274043 Review.
-
Lung cancer screening in patients with chronic obstructive pulmonary disease.Ann Transl Med. 2016 Apr;4(8):160. doi: 10.21037/atm.2016.03.57. Ann Transl Med. 2016. PMID: 27195278 Free PMC article. Review.
Cited by
-
Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.Chest. 2021 Nov;160(5):e427-e494. doi: 10.1016/j.chest.2021.06.063. Epub 2021 Jul 13. Chest. 2021. PMID: 34270968 Free PMC article.
-
The Diagnostic Value of Systemic Immune-Inflammatory Index (SII) and Lymphocyte-Albumin-Neutrophil Ratio (LANR) in Chronic Obstructive Pulmonary Disease with Lung Cancer.J Inflamm Res. 2024 Aug 20;17:5555-5565. doi: 10.2147/JIR.S474263. eCollection 2024. J Inflamm Res. 2024. PMID: 39185105 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical